Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRO283698 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| placebo | DRUG | Intravenous and subcutaneous ascending dose |
| PRO283698 | DRUG | Intravenous and subcutaneous ascending dose |
Inclusion Criteria: * RA diagnosed according to the American College of Rheumatology (ACR) Exclusion Criteria: * Female patients who are pregnant, plan to become pregnant during the study, or are breastfeeding * Clinically significant abnormal ECG * History of anaphylactic reactions * Positive he...
Top 20 of 28 competitors
PRO283698 is an investigational small molecule being studied for the treatment of rheumatoid arthritis. It is in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for its safety and pharmacokinetics in patients with this condition.
PRO283698 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY. The company is conducting clinical research to evaluate the drug's potential in treating rheumatoid arthritis.
PRO283698 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval. The Phase 1 trial has been completed, and the drug remains under evaluation for its safety and pharmacokinetic profile in patients with rheumatoid arthritis.
PRO283698 has one completed Phase 1 clinical trial registered as NCT00888745. This study, titled 'A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis,' enrolled 65 participants across the United States and Hungary. The trial was randomized, double-blind, and placebo-controlled.
PRO283698 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for rheumatoid arthritis. The drug has completed a Phase 1 trial, but it has not yet progressed through the later stages of clinical testing required for regulatory approval.
The specific molecular target of PRO283698 has not been disclosed in available information. As a small molecule being studied for rheumatoid arthritis, it is presumed to modulate pathways involved in the inflammatory process, but its exact mechanism of action remains under investigation in clinical trials.